dermatology

News

Sun Pharma reaches deal to buy out Taro in $347m deal

India’s Sun Pharma has signed an agreement to take full control of Israeli generic drugmaker Taro Pharmaceutical Industries, taking it into private hands.

News

MHRA imposes restrictions on acne drug in children

The UK medicines regulator has tightened up controls on the prescription of acne treatment isotretinoin to patients under the age of 18, following a review prompted by con

News

Almirall signs $210m bispecifics deal with EpimAb

A few months after raising €200 million in investment capital to boost its pipeline, Spanish drugmaker Almirall has used some of the cash for a bispecific antibody partner

News

AnaptysBio draws a bead on Bayer’s Spevigo after phase 3 win

After disappointing results in other indications, AnaptysBio has a route to market with its IL-36 receptor inhibitor imsidolimab in a rare and life-threatening form of the

R&D

Partner Content

Champion Innovation at the 7th Dermatology Drug Development ...

Following 6 FDA approvals of JAK inhibitors and the breakthroughs of the first approved therapies in Prurigo Nodularis, Alopecia Areata and a gene therapy for Dystrophic Epidermolysis Bullo

News

Leo builds dermatology pipeline with Timber deal

Denmark's Leo Pharma has agreed to buy US medical dermatology company Timber Pharmaceuticals in a move that will expand its pipeline of therapies for rare skin diseases.

Sun Pharma reaches deal to buy out Taro in $347m deal

MHRA imposes restrictions on acne drug in children

Almirall signs $210m bispecifics deal with EpimAb

AnaptysBio draws a bead on Bayer’s Spevigo after phase 3 win

Champion Innovation at the 7th Dermatology Drug Development ...

Leo builds dermatology pipeline with Timber deal

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

dermatology

Editor's Picks